Cargando…

Precision Medicine in Rare Diseases

Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Villalón-García, Irene, Álvarez-Córdoba, Mónica, Suárez-Rivero, Juan Miguel, Povea-Cabello, Suleva, Talaverón-Rey, Marta, Suárez-Carrillo, Alejandra, Munuera-Cabeza, Manuel, Sánchez-Alcázar, José Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709101/
https://www.ncbi.nlm.nih.gov/pubmed/33202892
http://dx.doi.org/10.3390/diseases8040042
_version_ 1783617680956194816
author Villalón-García, Irene
Álvarez-Córdoba, Mónica
Suárez-Rivero, Juan Miguel
Povea-Cabello, Suleva
Talaverón-Rey, Marta
Suárez-Carrillo, Alejandra
Munuera-Cabeza, Manuel
Sánchez-Alcázar, José Antonio
author_facet Villalón-García, Irene
Álvarez-Córdoba, Mónica
Suárez-Rivero, Juan Miguel
Povea-Cabello, Suleva
Talaverón-Rey, Marta
Suárez-Carrillo, Alejandra
Munuera-Cabeza, Manuel
Sánchez-Alcázar, José Antonio
author_sort Villalón-García, Irene
collection PubMed
description Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the world’s population. Many patients with rare diseases have suffered the consequences of what is called the diagnostic odyssey, that is, extensive and prolonged serial tests and clinical visits, sometimes for many years, all with the hope of identifying the etiology of their disease. For patients with rare diseases, obtaining the genetic diagnosis can mean the end of the diagnostic odyssey, and the beginning of another, the therapeutic odyssey. This scenario is especially challenging for the scientific community, since more than 90% of rare diseases do not currently have an effective treatment. This therapeutic failure in rare diseases means that new approaches are necessary. Our research group proposes that the use of precision or personalized medicine techniques can be an alternative to find potential therapies in these diseases. To this end, we propose that patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments.
format Online
Article
Text
id pubmed-7709101
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77091012020-12-03 Precision Medicine in Rare Diseases Villalón-García, Irene Álvarez-Córdoba, Mónica Suárez-Rivero, Juan Miguel Povea-Cabello, Suleva Talaverón-Rey, Marta Suárez-Carrillo, Alejandra Munuera-Cabeza, Manuel Sánchez-Alcázar, José Antonio Diseases Review Rare diseases are those that have a low prevalence in the population (less than 5 individuals per 10,000 inhabitants). However, infrequent pathologies affect a large number of people, since according to the World Health Organization (WHO), there are about 7000 rare diseases that affect 7% of the world’s population. Many patients with rare diseases have suffered the consequences of what is called the diagnostic odyssey, that is, extensive and prolonged serial tests and clinical visits, sometimes for many years, all with the hope of identifying the etiology of their disease. For patients with rare diseases, obtaining the genetic diagnosis can mean the end of the diagnostic odyssey, and the beginning of another, the therapeutic odyssey. This scenario is especially challenging for the scientific community, since more than 90% of rare diseases do not currently have an effective treatment. This therapeutic failure in rare diseases means that new approaches are necessary. Our research group proposes that the use of precision or personalized medicine techniques can be an alternative to find potential therapies in these diseases. To this end, we propose that patients’ own cells can be used to carry out personalized pharmacological screening for the identification of potential treatments. MDPI 2020-11-13 /pmc/articles/PMC7709101/ /pubmed/33202892 http://dx.doi.org/10.3390/diseases8040042 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Villalón-García, Irene
Álvarez-Córdoba, Mónica
Suárez-Rivero, Juan Miguel
Povea-Cabello, Suleva
Talaverón-Rey, Marta
Suárez-Carrillo, Alejandra
Munuera-Cabeza, Manuel
Sánchez-Alcázar, José Antonio
Precision Medicine in Rare Diseases
title Precision Medicine in Rare Diseases
title_full Precision Medicine in Rare Diseases
title_fullStr Precision Medicine in Rare Diseases
title_full_unstemmed Precision Medicine in Rare Diseases
title_short Precision Medicine in Rare Diseases
title_sort precision medicine in rare diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709101/
https://www.ncbi.nlm.nih.gov/pubmed/33202892
http://dx.doi.org/10.3390/diseases8040042
work_keys_str_mv AT villalongarciairene precisionmedicineinrarediseases
AT alvarezcordobamonica precisionmedicineinrarediseases
AT suarezriverojuanmiguel precisionmedicineinrarediseases
AT poveacabellosuleva precisionmedicineinrarediseases
AT talaveronreymarta precisionmedicineinrarediseases
AT suarezcarrilloalejandra precisionmedicineinrarediseases
AT munueracabezamanuel precisionmedicineinrarediseases
AT sanchezalcazarjoseantonio precisionmedicineinrarediseases